Research Analysts Set Expectations for VTVT Q1 Earnings

vTv Therapeutics Inc. (NASDAQ:VTVT) – HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of vTv Therapeutics in a report issued on Wednesday, March 11th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings per share of $0.99 for the quarter, up from their previous forecast of $0.96. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.51. The firm had revenue of ($0.02) million during the quarter.

A number of other analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. Roth Mkm started coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. Wall Street Zen upgraded shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a research report on Wednesday. Finally, TD Cowen began coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They set a “buy” rating on the stock. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $55.25.

vTv Therapeutics Trading Up 0.2%

Shares of vTv Therapeutics stock opened at $35.10 on Thursday. The firm has a market cap of $138.29 million, a P/E ratio of -10.48 and a beta of 0.44. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The stock’s fifty day moving average price is $36.18 and its 200-day moving average price is $29.26.

Hedge Funds Weigh In On vTv Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTVT. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the fourth quarter worth about $221,000. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics in the 4th quarter valued at about $731,000. Geode Capital Management LLC boosted its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP grew its position in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.